USANA Health Sciences (NYSE:USNA) Sets New 12-Month Low at $37.05

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as $37.05 and last traded at $37.23, with a volume of 5929 shares trading hands. The stock had previously closed at $37.70.

Analyst Ratings Changes

A number of analysts have weighed in on USNA shares. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Wednesday, July 24th. DA Davidson cut their price objective on shares of USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating on the stock in a report on Thursday, July 25th.

USANA Health Sciences Trading Down 4.1 %

The firm has a market cap of $689.07 million, a price-to-earnings ratio of 11.27, a P/E/G ratio of 1.26 and a beta of 0.90. The firm has a 50 day moving average price of $41.92 and a 200-day moving average price of $45.01.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The company had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. During the same period in the prior year, the company earned $0.89 EPS. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Myron W. Wentz sold 13,496 shares of USANA Health Sciences stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the sale, the insider now directly owns 7,864,345 shares in the company, valued at $354,131,455.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, major shareholder Myron W. Wentz sold 2,202 shares of the company's stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $47.79, for a total transaction of $105,233.58. Following the completion of the transaction, the insider now directly owns 7,877,841 shares in the company, valued at $376,482,021.39. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Myron W. Wentz sold 13,496 shares of the business's stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $45.03, for a total value of $607,724.88. Following the sale, the insider now owns 7,864,345 shares in the company, valued at $354,131,455.35. The disclosure for this sale can be found here. Insiders sold a total of 23,638 shares of company stock valued at $1,024,629 over the last 90 days. 0.33% of the stock is owned by company insiders.

Institutional Trading of USANA Health Sciences

Large investors have recently made changes to their positions in the business. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 24.4% during the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company's stock worth $44,183,000 after purchasing an additional 191,289 shares during the period. Dimensional Fund Advisors LP raised its position in shares of USANA Health Sciences by 0.6% during the second quarter. Dimensional Fund Advisors LP now owns 683,158 shares of the company's stock worth $30,907,000 after purchasing an additional 3,889 shares during the period. Pacer Advisors Inc. raised its position in shares of USANA Health Sciences by 14.3% during the second quarter. Pacer Advisors Inc. now owns 467,352 shares of the company's stock worth $21,143,000 after purchasing an additional 58,597 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of USANA Health Sciences by 4.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 222,423 shares of the company's stock worth $11,922,000 after purchasing an additional 8,536 shares during the period. Finally, American Century Companies Inc. grew its holdings in shares of USANA Health Sciences by 12.3% during the second quarter. American Century Companies Inc. now owns 159,782 shares of the company's stock worth $7,229,000 after buying an additional 17,460 shares in the last quarter. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.